Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PPID | Q08752 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PPIB | P23284 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | PPIG | Q13427 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11037833 | 0.98 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOAHTT | |
| SCHEMBL25534680 | 0.85 | ADRB2 (0.41) | LMNAHTTSMN1; SMN2TSHRMEN1 | |
| SCHEMBL3279844 | 0.85 | KMT2A (0.47) | LMNAHTTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL22838092 | 0.84 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOAHTT | |
| SCHEMBL9235662 | 0.83 | ESR1 (0.53) | LMNACYP1A2CYP3A4ALDH1A1KDM4E | |
| SCHEMBL9232941 | 0.83 | ESR1 (0.53) | LMNACYP1A2CYP3A4ALDH1A1KDM4E | |
| SCHEMBL1792502 | 0.83 | ESR1 (0.53) | LMNACYP1A2CYP3A4ALDH1A1KDM4E | |
| SCHEMBL1041487 | 0.83 | LMNA (0.56) | LMNACYP1A2CYP3A4MAOAHTT | |
| SCHEMBL11358690 | 0.83 | PTGS2 (0.46) | LMNACYP1A2ALDH1A1KDM4ETSHR | |
| SCHEMBL13884372 | 0.82 | EPHX1 (0.45) | LMNATSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135831-A | Preparation method of alminoprofen intermediate | 深圳市华先医药科技有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-113135831-A | Preparation method of alminoprofen intermediate | 深圳市华先医药科技有限公司 | 2021-07-20 | — | — | CN | disclosed |
| WO-2021027721-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| CN-111646911-A | Method for synthesizing o-aminoacetophenone | 广东莱佛士制药技术有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-4316850-A | ANTINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-02-23 | — | — | US | disclosed |
| US-4264619-A | Tertiary aminoacids | CIBA-GEIGY CORPORATION (US) | 1981-04-28 | — | — | US | disclosed |
| US-4237298-A | Aromatic acetic acid derivatives having sulfur atom at alpha-position and process for their preparation | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1980-12-02 | — | — | US | disclosed |
| EP-0011142-A1 | Pyrido (2,1-b) quinazolinones, their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-05-28 | — | — | EP | disclosed |
| US-4163788-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1979-08-07 | — | — | US | disclosed |
| US-4144248-A | Aromatic acetic acid derivatives having sulfur atom at alpha-position and process for their preparation | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1979-03-13 | — | — | US | disclosed |
| US-4126691-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
| US-4118504-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | Erba, Carlo (IT) | 1978-10-03 | — | — | US | disclosed |
| US-4116972-A | ANTI-INFLAMMATORY 1-OXO-ISOINDOLINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | FUJI CHEMICAL INDUSTRY COMPANY LIMITED (JP) | 1978-09-26 | — | — | US | disclosed |
| US-3997669-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LMNA 3015/4885CYP1A2 3832/4885CYP3A4 4198/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LMNA 3243/4885CYP1A2 3276/4885CYP3A4 3280/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LMNA 3015/4885CYP1A2 3832/4885CYP3A4 4198/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LMNA 3115/4885CYP1A2 3709/4885CYP3A4 4148/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LMNA 3115/4885CYP1A2 3709/4885CYP3A4 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.